Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone XR in rheumatoid arthritis: anti-inflammatory and metabolic effects
2004-000482-35Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rosiglitazone XR 8 mg once daily with Placebo once daily (2 arms). Primary endpoint: Disease Activity Score 28 (DAS28) at 6 months. Started Feb 2005; status: completed.
02
Drugs
rosiglitazone
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2004-000482-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000482-35.